| abstract |
Disclosed is a morpholine compound represented by the formula (I) or a pharmacologically acceptable salt thereof, wherein (a) R1, R2, R3 and R4 are the same or different and each represent a hydrogen atom or an alkyl group, X1 represents an alkylene group, wherein the alkylene group may be substituted with 1 to 3 hydroxyl groups or alkyl groups, wherein the alkyl groups may be substituted with 1 to 3 hydroxyl groups, or a cycloalkyl group formed by two alkyl groups together bonded to the same carbon atom of the alkylene group, Xa represents a methoxy group or a fluorine atom, Xb represents an oxygen atom and Ar1 represents an optionally substituted aryl group, pyridinyl group, aryloxy group, or pyridinyloxy group. (b) Ar1-X1- represents a cycloalkyl group as defined in the specification (c) one of R1and R2 and one of R3 and R4 are the same or different and each represent a hydrogen atom or an alkyl group; the other of R1 and R2 and the other of R3 and R4 together with the carbon atoms to which they are respectively bonded, form a cycloalkyl group, wherein the cycloalkyl group may be optionally substituted. (d) Ar1-X1- and R4 together with the nitrogen atom to which Ar1-X1- is bonded and the carbon atom to which R4 is bonded, form a 4- to 8-membered nitrogen containing heterocyclic group that may be substituted as defined in the specification (e) R1 and R2 together with the carbon atom to which they are bonded, form a cycloalkyl group. (f) R3 and R4, together with the carbon atom to which they are bonded, form a cycloalkyl group. Also disclosed is a composition comprising the compound and the use of the compound in the production of a medicament to treat a disease caused by amyloid beta. |